Why Is Alkermes Stock Falling On Monday? - Alkermes (NASDAQ:ALKS)

Why Is Alkermes Stock Falling On Monday? - Alkermes (NASDAQ:ALKS)

Alkermes plc (NASDAQ:ALKS) on Monday released topline results from the randomized double-blind treatment period of the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1). Narcolepsy is a chronic neurological disorder that disrupts the body’s ability to regulate sleep-wake cycles. It’s characterized by excessive daytime sleepiness and sudden, uncontrollable sleep attacks. Alixorexton, formerly ALKS 2680, is a…

Alkermes narcolepsy drug headed for late-stage testing

Part of a class of therapies that boost “orexin” proteins, the drug just scored positive results in a Phase 2 trial. Analysts have guessed it could ultimately generate billions in sales.

Alkermes drug helped narcolepsy patients stay awake in Phase 2 trial

The company says the results suggest the treatment, called alixorexton, could also help improve fatigue and cognition.

Once-Daily Alixorexton Improves Wakefulness at All Doses in Patients With Narcolepsy Type 1

In the double-blind portion of Vibrance-1, alixorexton improved wakefulness while eliciting broad benefits in patient-reported outcomes.

Alkermes Advances Narcolepsy Drug Following Positive Study Results

Alkermes has announced promising results of its drug, alixorexton, from a study which enrolled individuals with narcolepsy type 1, characterized by excessive sleepiness and sudden muscle control loss. The study demonstrated that all three doses of alixorexton significantly improved wakefulness compared to a placebo, with participants taking over 20 minutes to fall asleep, indicating “normative wakefulness.” The drug was well-tolerated, with no s…

Positive Phase 2 Data: Alixorexton for the Treatment of Adults With Narcolepsy Type 1

Positive phase 2 results show that treatment with alixorexton led to statistically significant and dose-dependent improvements in sleep latency among patients with narcolepsy type 1.